¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Vitamin B group"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªºÐ¼®(¹ý)
  • Rh blood group system
    ¾Ë¿¡ÃëÇ÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • haptenic group
    ÇÕÅÙ±â(¡­Ðñ).
  • hearing aid, group
    Áý´Üº¸Ã»±â
  • high risk group
    °íÀ§Çèµµ±º(Ë­Ëô̴̬˴).
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(¡­Ðñ).
  • incompatibility group, plasmid
    ÇÃ¶ó½º¹Ìµå ºñÀûÇÕ±º
  • indeterminate group
    ¹ÌÁ¤Çü±º(Ú±ïÒúþÏØ).
  • indeterminate group
    ¹ÌÁ¤Çü±º(ËÑËøÌ´Ë´).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ)
  • prepaid group practice
    ¼±ºÒÁ¦Áý´Ü°³¿ø.
  • prostheitc group
    ¹èÇÕ±º(ÛÕùêÏØ).
  • prosthetic group-labeled enzyme
    º¸Á¶±ºÇ¥ÁöÈ¿¼Ò
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªÃøÁ¤(¹ý)
  • psittacosis-lymphogranuloma-trachoma (PLT) group
    PLT±º Ŭ¶ó¹Ìµð¾Æ
  • psittacosis-lymphogranuloma-trachoma group
    ¾Þ¹«(»õ)º´ ¸²ÇÁÀ°¾ÆÁ¾Áõ Æ®¶óÄÚ¸¶±º(¡­ë¿ä´ðþñø¡­ÏØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • vitamin e deficiency,antioxidant function
    Ç×»êÈ­Á¦±â´É
  • vitamin k deficiency
    ºñŸ¹ÎK°áÇÌ(Áõ)
  • vitamin preparation
    ºñŸ¹ÎÁ¦(¡­ð¥).
  • vitamin requirement
    ºñŸ¹ÎÇʿ䷮ (¡­ù±é©åÖ).
  • vitamin unit
    ºñŸ¹Î´ÜÀ§(¡­Ó¤êÈ).
  • vitamin,fat soluble
    Áö¿ë¼º(ò·éÁàõ)
  • vitamin,water soluble
    ¼ö¿ë¼º(â©éÁàõ)
  • water soluble vitamin
    ¼ö¿ë¼º(â©éÁàõ) ºñŸ¹Î.
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • analytic group psychotherapy
    ºÐ¼®Àû Áý´Ü Á¤½ÅÄ¡·á
  • anterior sinus group
    ÀüºÎºñµ¿±º
  • atomic group
    ¿øÀÚ´Ü.
  • audiometry, group
    Áý´Üû·Â°Ë»ç
  • basic food group
    ±âÃʽÄǰ±º(¡­ãÝù¡ÏØ).
  • behavioral group therapy
    Áý´ÜÇൿġ·á(¿ä¹ý)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • diazonium group
    µð¾ÆÁ¶´½ ±â(Ðñ)
  • earthy group
    Å伺±â(÷ÏàõÐñ)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
  • glycoaldehyde group
    ±Û¶óÀÌÄھ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycolaldehyde group
    ±Û¶óÀÌÄݾ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycoloyl group
    ±Û¶óÀÌÄÚ·ÎÀϱâ(Ðñ)
  • glycolyl group
    ±Û¶óÀÌÄÚ¸±±â(Ðñ)
  • glycosyl group
    ±Û¶óÀÌÄڽDZâ(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CREG Cross REactive Group (of HLA Antigens)
ECOG Eastern Cooperative Oncology Group
GAP Group for Advancement of Psychiatry
GBS   1) Guillain-Barr Syndrome
    = PIP; Post-Infectious Polyneuropat...
Gc globulin Group-specific complement globulin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
VA Vitamin A
VITA Vitamin A
VAD Vitamin A deficiency
VAD Vitamin A-deficient
VB12 Vitamin B12
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
vitamin K2(35) Menaquinone-6 with a 3-heptaprenyl side chain.
Synonym: vitamin K2(35).
(05 Mar 2000)
vitamin K3 A fat soluble vitamin that plays an important role in blood clotting.
(27 Sep 1997)
vitamin K4 2-Methyl-1,4-naphthohydroquinone diacetate;menadiol acetylated at both OH groups; a prothrombogenic vitamin.
Synonym: acetomenaphthone, vitamin K4.
(05 Mar 2000)
vitamin K5 4-amino-2-methyl-1-naphthol;an antihemorrhagic vitamin.
(05 Mar 2000)
vitamin k deficiency A nutritional condition produced by a deficiency of vitamin k in the diet, characterised by an increased tendency to haemorrhage (haemorrhagic diathesis). Such bleeding episodes may be particularly severe in newborn infants.
(12 Dec 1998)
vitamin K epoxidase <enzyme> Reductase is the reverse reaction of the epoxidase
Registry number: EC 1.14.99.-
Synonym: vitamin k epoxide reductase, menadione epoxide reductase, vitamin k 2,3-epoxide reductase, phylloquinone epoxide reductase, vitamin ko reductase
(26 Jun 1999)
vitamin K unit See: Dam unit.
(05 Mar 2000)
vitamin P A mixture of bioflavonoids extracted from plants (especially citrus fruits). It reduces the permeability and fragility of capillaries and is useful in the treatment of certain cases of purpura that are resistant to vitamin C therapy.
See: hesperidin, quercetin, rutin.
Synonym: capillary permeability factor, citrin, permeability vitamin.
(05 Mar 2000)
vitamin PP A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
vitamin u <chemical> A vitamin found in green vegetables. It is used in the treatment of peptic ulcers, colitis, and gastritis and has an effect on secretory, acid-forming, and enzymatic functions of the intestinal tract.
Pharmacological action: anti-ulcer agents, gastrointestinal agents.
Chemical name: Sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride, (S)-
(12 Dec 1998)
metabolised vitamin D milk Milk produced by feeding irradiated yeast to cows; standardised to contain not less than 400 USP units per quart.
(05 Mar 2000)
permeability vitamin A mixture of bioflavonoids extracted from plants (especially citrus fruits). It reduces the permeability and fragility of capillaries and is useful in the treatment of certain cases of purpura that are resistant to vitamin C therapy.
See: hesperidin, quercetin, rutin.
Synonym: capillary permeability factor, citrin, permeability vitamin.
(05 Mar 2000)
microbial vitamin A substance necessary for the growth of certain microorganisms, e.g., biotin, p-aminobenzoic acid.
(05 Mar 2000)
coagulation vitamin An obsolete term for vitamin K.
(05 Mar 2000)
Sherman-Bourquin unit of vitamin B2 The amount of vitamin B2 required in the diet daily to sustain an average weekly gain of 3 g for 8 weeks in standard test rats; one unit is equivalent to 1 to 7 ug (0.001 to 0.007 mg) of riboflavin, depending on the deficiency diet used in the above assay.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á